


From: Macfadden, Wayne
Sent: 3/29/2002 3:38:41 PM
To: REDACTED
CC:
Subject: MOVies, etc



Hello again, my Venus Princess,

Back from the movies.....(Clockstoppers)..diverting, but it was so hyped-up, that my kids knew all the punch lines and plot in advance..anyway, at least it kept the families quiet for a while, and not bickering..

I was wondering what you were doing at this time....must be 8P or so....perhaps giving yourself a bubble bath with candlelite, REDACTED
? (Am I even close??)

OK, since I am officially on the meter (i.e. working) today, a few words re: drug abuse

I think a dual diagnosis trial would be great, good for the field, perhaps of interest to your site. Briefly, one of these 2 designs would be preferable

(but if you , Lyn, or anyone else has other ideas, bring them on!).

- a crossover type design, where pts using drugs actively on Ris, or Olz are monitored for their drug use, then after a certain period of time, switched to SQL, and monitored again
- Pts using drugs on Ris or Olz would be monitored, then switched in a blinded fashion to either rx with same, or SQL (or perhaps haldol as a 3rd arm, if you folks are using much of that)

(by the way, what drugs of abuse are common at your site?)

An imaging study of some sort may be interesting, but those are notoriously difficult to demonstrate separations between arms, and the clinical significance is always an issue

I am on the team that reviews global IIT's as well as the US team, so I would do my best to get it funded, but a few caveats:

- I'm an invited guest on the global team, not the lead medic like I am in the states, so my influence may be less
- most importantly, the global program is not nearly funded as well as the US program, so a relatively small budget would be necessary (under 50,000 USD)
- As you might imagine, a drug company's main interest is showing effect of their treatment; CBT, or any other psychosocial or therapy type of rx would not be encouraged, and may be necessary to curtail or delete, as it probably dilute out any effect

despite the above, it would be really exciting if you folks took this on.....I realize it would be even more work....but I don't think we have any European data on studies like this...not to mention great excuses to rendez- vous..

Ok, enough business.....'hope you are enjoying the weekend, and know that I

am thinking of you often REDACTED

XO,

W

Wayne Macfadden MD
Director, Clinical Research
CNS Therapeutic Area
AstraZeneca LP
302-886-1147

(thought I'd put in my official signature, since business was discussed.....)